ArticleJACC. Case reports2026
Successful Everolimus Therapy for Atrioventricular Block Due to Cardiac Rhabdomyoma Associated With Tuberous Sclerosis Complex.
Article in JACC. Case reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- From Genotype to Cardiac Phenotype: Cardiovascular Involvement in Syndromic and Metabolic Disorders.International journal of molecular sciences · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundCardiac rhabdomyoma (CR) associated with the tuberous sclerosis complex can cause atrioventricular (AV) block (AVB) by compressing the AV node. Everolimus, an mTOR inhibitor, is known to shrink these tumors and alleviate obstruction and tachycardia; however, improvement in AVB has not been previously described. CASE SUMMARY: A 25-year-old woman was found to have a fetus with subependymal nodules and multiple CRs. After birth, an electrocardiogram demonstrated a persistent 2:1 AVB with a ventricular rate of 60 to 70 beats/min. Echocardiography revealed CRs, including one near the AV node. Everolimus was initiated before considering permanent pacemaker implantation. CRs regressed on echocardiography, and the AVB resolved. After discontinuation of everolimus, no tumor regrowth was observed. DISCUSSION: In this case, the AVB resolved with rhabdomyoma regression. Although permanent pacemaker implantation was initially considered, everolimus successfully prevented further therapy. TAKE-HOME MESSAGE: Everolimus may be a therapeutic option for AVB due to CR compressing the AV node.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.